GLP-1 Medications and Sexual Health: What a Change Might Mean

If sexual desire or function changes after you start a GLP-1 medication, you may wonder whether the prescription caused it, whether weight loss is changing how you feel in your body, or whether something else needs attention. There is no single answer for everyone. Reports and early research describe changes in both directions, while drug-specific evidence is still limited. A change is worth discussing with your clinician even when its cause is uncertain.

“Sexual side effects” can mean different things: lower or higher desire, difficulty with arousal or erections, pain or dryness, changes in orgasm, or a shift in comfort with intimacy. Naming the actual change matters more than attaching a cause to it right away.

What do we know about a direct drug effect?

For a concrete label example, Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. The current U.S. prescribing information lists the most common adverse reactions as gastrointestinal symptoms and decreased appetite; it does not list sexual dysfunction among them. A label’s common-reaction list cannot rule out uncommon or less-studied experiences. It also cannot tell you whether a symptom during treatment came from the drug, diabetes, another medication, weight change, or a relationship or life event. Different GLP-1 medicines have different labels, so your own product’s prescribing information matters.

Research is developing, but it does not justify a blanket promise of harm or improvement. A 2026 U.S. electronic-health-record study compared men with type 2 diabetes starting a GLP-1 receptor agonist with men starting a different diabetes drug. It found a modestly higher rate of new erectile-dysfunction diagnoses in the GLP-1 group before one bias-calibration step; after that step, the association was no longer statistically clear. The authors said observational bias could explain the finding and that it does not establish causation. That study cannot be generalized to every GLP-1 product, to people without diabetes, or to all forms of sexual health. Both this study and the small-study review below involve men, so they cannot answer questions about desire, pain, dryness, or orgasm in other populations.

A separate review of seven small studies involving 680 men with overweight or obesity found changes in some hormone measures and erectile-function scores during GLP-1 treatment. Its authors could not show a direct drug effect on testicular function. Together, these studies show why “GLP-1s cause erectile dysfunction” and “GLP-1s improve sex” both overstate what is known.

The wider picture matters

Sexual health can change alongside appetite, energy, mood, sleep, chronic conditions, other prescriptions, and body image. These are possible contributors to explore with a clinician, not a checklist for diagnosing yourself. For example, diabetes and vascular health can affect erections; discomfort, nausea, or exhaustion can affect interest in sex without implying a new hormone disorder. Someone else may feel more comfortable with their body or more interested in intimacy as treatment progresses. The direction and meaning of change are personal.

A 2025 Kinsey Institute survey illustrates that variation. Among 155 U.S. single adults in its larger survey who reported using a GLP-1 for weight loss, 18% said sexual desire increased and 16% said it decreased; 16% reported improved sexual function and 12% reported worse function. These were self-reports from a small subgroup, not a drug trial. They show a range of experiences, not the odds that a medication will change your sex life.

A private, useful way to prepare for an appointment

You do not need to disclose intimate details in an app or to anyone beyond your care team. If you want to prepare a private note, keep it brief:

• What changed: desire, arousal, erection, comfort, pain, orgasm, or something else?
• When did it begin? Was it before or after a new medicine or dose change?
• What else changed around that time: sleep, mood, weight, another prescription, alcohol use, or an existing condition?
• How much does it bother you, and what would you like help with?

You can open with: “Since starting this medicine, I’ve noticed a change in sexual function. I’m not sure why. Could we review possible causes and what needs checking?” A clinician can decide whether to review medications, screen for a condition, discuss pain or dryness, or refer you to a specialist. Do not stop or change a prescribed drug solely to test a theory without discussing it with the prescriber.

Tell a clinician about pain during sex, new genital bleeding, a sudden functional change, or symptoms that worry you. Persistent distress also deserves care; you do not have to wait for a symptom to become severe before bringing it up.

One reproductive-health detail that does have a clear label instruction

Sexual function and fertility are different questions. The Mounjaro label says its delayed gastric emptying can reduce the effectiveness of oral hormonal contraceptives. It advises people using them to switch to a non-oral method or add a barrier method for four weeks after starting Mounjaro and for four weeks after each dose increase. This is a product-specific instruction, not evidence that Mounjaro improves fertility or changes libido. If pregnancy is possible, ask your prescriber or pharmacist how the guidance applies to your contraception. Check the instructions for your own medication rather than assuming all GLP-1 drugs have the same advice.

A sexual-health change during GLP-1 treatment is a valid reason to ask questions. The most helpful conversation starts with the symptom and its timing, then considers several possible explanations. Current evidence leaves room for uncertainty, and that is precisely why your care plan should be personal.

Cover image: Rhoda Baer / National Cancer Institute, public domain; resized and converted to WebP.